3VG.F

Healthcare Biotechnology

THX Pharma Société Anonyme

€3.31

-0.00 -0.15% today

Price History

Not enough data

Key Stats

Market Cap

47.89M

Avg Volume

310

EPS

-€0.11

52W High

€4.49

52W Low

€1.51

Div. Yield

0.0%

Valuation

P/B Ratio

15.74

P/S Ratio

59.41

EV/EBITDA

-10.33

EV/Revenue

50.51

Margins

Gross Margin (177.0%)

Operating Margin (144876610.0%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(100.0%)

Return on Equity

(482.4%)

Return on Assets

(35.4%)

Liquidity & Leverage

Current Ratio

2.35

Quick Ratio

2.32

Debt / Equity

0.99

Total Cash

7.77M

Total Debt

2.88M

About

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.